flow trial semaglutide kidney outcomes 2024 Shows Benefit of in Type 2 Diabetes and Chronic Disease: EASD Study: Semaglutide slowed progression of

SKU: 37080152080

Pay in 4 interest-free payments of $5.68 Learn more

Live Spec

Study: Semaglutide slowed progression of CKD, cut cardiovascular events, mortality risk The FLOW trial for semaglutide kidney outcomes in T2DM halted due to interim results meeting efficacy criteria FLOW is a RCT comparing injectable semaglutide 1.0 mg with placebo as an adjunct Get With the FLOW! in: Kidney News Volume 16 Issue 8 (2024) Patients with type 2 #diabetes and chronic kidney disease are at high risk for kidney failure, cardiovascular events, and death. Whether treatment with semaglutide would mitigate these risks is unknown. Journal Club: FLOW Trial Review The FLOW Trial, published in The New England Journal of Medicine (May 2024), evaluated the effects of semaglutide on kidney disease in patients with type AHA 2024: semaglutide continues to impress in diabetic kidney disease Clinical Trials Arena

Store: clickpoint.com.au · Domain: clickpoint.com.au